GLSI Stock Summary and Trading Ideas (Greenwich Lifesciences | NASDAQ:GLSI)

Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9-amino-acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including breast cancers at low (1+), intermediate (2+), and high (3+ or overexpressing) levels.

Greenwich Lifesciences trades on the NASDAQ stock market under the symbol GLSI.

As of October 23, 2026, GLSI stock price climbed to $16.03 with 86,226 million shares trading.

GLSI has a beta of 2.60, meaning it tends to be more sensitive to market movements. GLSI has a correlation of 0.12 to the broad based SPY ETF.

GLSI has a market cap of $214.29 million. This is considered a Small Cap stock.

In the last 3 years, GLSI traded as high as $34.10 and as low as $7.58.

The top ETF exchange traded funds that GLSI belongs to (by Net Assets): VTI, IWM, VXF, IWO, VTWO.

GLSI has outperformed the market in the last year with a return of +74.4%, while the SPY ETF gained +14.3%. In the last 3 month period, GLSI beat the market returning +21.5%, while SPY returned +3.2%. However, in the most recent 2 weeks GLSI has underperformed the stock market by returning -3.0%, while SPY returned -2.4%.

GLSI support price is $14.60 and resistance is $16.36 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GLSI shares will trade within this expected range on the day.